Literature DB >> 24491410

Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?

Felix P Kuhn1, Martin Hüllner, Caecilia E Mader, Nikos Kastrinidis, Gerhard F Huber, Gustav K von Schulthess, Spyros Kollias, Patrick Veit-Haibach.   

Abstract

UNLABELLED: Considering PET/MR imaging as a whole-body staging tool, scan time restrictions in a single body area are mandatory for the cost-effective clinical operation of an integrated multimodality scanner setting. It has to be considered that (18)F-FDG already acts as a contrast agent and that under certain circumstances MR contrast may not yield additional clinically relevant information. The concept of the present study was to understand which portions of the imaging information enhance the sensitivity and specificity of the hybrid examination and which portions are redundant.
METHODS: One hundred fifty consecutive patients referred for primary staging or restaging of head and neck cancer underwent sequential whole-body (18)F-FDG PET with CT-based attenuation correction, contrast-enhanced (ce) CT, and conventional diagnostic MR imaging of the head and neck in a trimodality PET/CT-MR system. Assessed were image quality, lesion conspicuity, diagnostic confidence, and the benefit of additional coronal and sagittal imaging planes in cePET/CT, PET/MR imaging with only T2-weighted fat-suppressed images (T2w PET/MR imaging), and cePET/MR imaging.
RESULTS: In 85 patients with at least 1 PET-positive lesion, 162 lesions were evaluated. Similar robustness was found for CT and MR image quality. T2w PET/MR imaging performed similarly to (metastatic lymph nodes) or better than (primary tumors) cePET/CT in the morphologic characterization of PET-positive lesions and permitted the diagnosis of necrotic or cystic lymph node metastasis without application of intravenous contrast medium. CePET/MR imaging yielded a higher diagnostic confidence for accurate lesion conspicuity (especially in the nasopharynx and in the larynx), infiltration of adjacent structures, and perineural spread.
CONCLUSION: The results of the present study provide evidence that PET/MR imaging can serve as a legitimate alternative to PET/CT in the clinical workup of patients with head and neck cancers. Intravenous MR contrast medium may be applied only if the exact tumor extent or infiltration of crucial structures is of concern (i.e., preoperatively) or if perineural spread is anticipated. In early assessment of the response to therapy, in follow-up examinations, or in a whole-body protocol for non-head and neck tumors, T2w PET/MR imaging may be sufficient for coverage of the head and neck. The additional MR scanning time may instead be used for advanced MR techniques to increase the specificity of the hybrid imaging examination.

Entities:  

Keywords:  PET/CT; PET/MRI; head and neck cancer; oncological imaging

Mesh:

Substances:

Year:  2014        PMID: 24491410     DOI: 10.2967/jnumed.113.125443

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  41 in total

1.  PET/MRI and PET/CT: is there room for both at the top of the food chain?

Authors:  Torsten Kuwert; Philipp Ritt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-19       Impact factor: 9.236

2.  Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

Authors:  Christopher Klenk; Rakhee Gawande; Vy Thao Tran; Jennifer Trinh Leung; Kevin Chi; Daniel Owen; Sandra Luna-Fineman; Kathleen M Sakamoto; Alex McMillan; Andy Quon; Heike E Daldrup-Link
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

3.  Diagnostic and prognostic value of 18F-FDG PET, CT, and MRI in perineural spread of head and neck malignancies.

Authors:  Laurent Dercle; Dana Hartl; Laura Rozenblum-Beddok; Fatima-Zohra Mokrane; Romain-David Seban; Randy Yeh; François Bidault; Samy Ammari
Journal:  Eur Radiol       Date:  2017-10-30       Impact factor: 5.315

4.  Perineural spread-susceptible structures: a non-pathological evaluation of the skull base.

Authors:  Francisco J Barrera-Flores; Natalia Villarreal-Del Bosque; Alejandro Díaz González-Colmenero; Carolina Garza-González; Rodolfo Morales-Ávalos; Ricardo Pinales-Razo; Guillermo Elizondo-Riojas; Santos Guzmán-López; Rodrigo E Elizondo-Omaña
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-07       Impact factor: 2.503

5.  FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.

Authors:  Yuko Suenaga; Kazuhiro Kitajima; Takeaki Ishihara; Ryohei Sasaki; Naoki Otsuki; Ken-Ichi Nibu; Tsutomu Minamikawa; Naomi Kiyota; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2015-07-19       Impact factor: 5.315

6.  Integrated versus separate reading of F-18 FDG-PET/CT and MRI for abdominal malignancies - effect on staging outcomes and diagnostic confidence.

Authors:  Lisa A Min; Wouter V Vogel; Max J Lahaye; Monique Maas; Maarten L Donswijk; Erik Vegt; Miranda Kusters; Henry J Zijlmans; Katarzyna Jóźwiak; Sander Roberti; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2019-05-22       Impact factor: 5.315

Review 7.  [Molecular imaging of head and neck cancers : Perspectives of PET/MRI].

Authors:  P Stumpp; S Purz; O Sabri; T Kahn
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

Review 8.  PET/MRI: Technical Challenges and Recent Advances.

Authors:  Jin Ho Jung; Yong Choi; Ki Chun Im
Journal:  Nucl Med Mol Imaging       Date:  2016-01-26

Review 9.  18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.

Authors:  Claudio Spick; Ken Herrmann; Johannes Czernin
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

Review 10.  Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.

Authors:  Kazuhiro Kitajima; Yasuhiko Ebina; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2014-04-18       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.